The finalized international pricing model covers too few drugs to meaningfully reduce Medicare spending

After exemptions and deal-making, the GLOBE model applies to a small fraction of the drugs driving Medicare costs.

Overview Debates Related claims Topics Sources

Medicare for All is a viable solution to the U.S. healthcare crisis

Placebo-controlled trials should be required before approving new medicines

Updated vaccines should undergo full clinical trials before approval

New medicines should have to outperform existing treatments before approval

Governments should license publicly funded drug patents to competitors when prices are unaffordable

Pharmaceutical companies have too much influence over healthcare

Healthcare costs will be the deciding issue in the 2026 midterm elections

Million-dollar price tags for ultra-rare disease treatments are justified to incentivize drug development

Voluntary pricing agreements with drugmakers are more effective than mandatory controls

Tying Medicare drug prices to international benchmarks will lower patient costs without reducing access to treatments

Exempting drugmakers that struck voluntary price deals from the mandatory pricing model undermines the program

Pharmaceutical companies are right to challenge the mandatory pricing model in court

The federal government should cap out-of-pocket healthcare costs for all Americans

Serapha Bio should halt development of its SERP-01 therapy during the Beam lawsuit

Merck's lung cancer drug poses unacceptable safety risks to patients

The FDA was justified in rejecting Merck's accelerated approval bid for its lung cancer drug

The FDA should approve UniQure's AMT-130 for Huntington's disease

External control groups are reliable for evaluating experimental gene therapies

Medicare Part B premiums should be means-tested more aggressively

The Part D premium stabilization rule should be made permanent